Arrowhead Pharmaceuticals is licensing one of its drug candidates, a hepatitis B treatment, to a subsidiary of pharmaceutical giant Johnson & Johnson in a cash and stock deal valued at $250 million up front.
The agreement announced Thursday comes one month after Pasadena, CA-based Arrowhead, which operates its laboratories in Madison, WI, reported encouraging early data from a small clinical trial suggesting its drug could successfully treat hepatitis B viral infections. It also follows the recent FDA approval of an Alynlam Pharmaceuticals drug that takes the same approach to treating disease as Arrowhead’s experimental therapy.
Under the terms of the deal,… Read more »
UNDERWRITERS AND PARTNERS